Page 36 - Groupb Strep News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Group B Strep: Tyrone mum raising awareness of life-threatening infection in newborn babies Baby Pàdraig became lifeless eight hours after birth due to the infection Updated Baby Pàdraig became very ill after birth Never miss a thing from Belfast and beyond - sign up for FREE newsletter direct to your inboxInvalid EmailSomething went wrong, please try again later. Subscribe When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplain...

If we could describe 2020 in one word for posterity, it’d no doubt be “memorable.” Hopefully it will also be anomalous. This year was largely defined by the COVID-19 pandemic, which led to global disruption, ripped milestones from our routines and created a justifiable (and lingering) amount of concern and anxiety. That’s not to say it wasn’t hard at times (it was), but our faculty, staff and students stepped up to the challenge – and then some. Consider UofL’s response to this extraordinary virus as an example. From the onset, our nationally networked lab enabled researchers to...

Share: COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ -- MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington Partners, Adjuvant Capital, and Industrifonden, along with existing investors Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures, and LF Investment. Proceeds will advance the clinical development of MinervaX's novel GBS vaccine through Phase II clinical trials,...

ST. JOHNSBURY — Quickly identifying a highly contagious disease is key to both containing the spread and treating the patient. Northeastern Vermont Regional Hospital (NVRH) now has a new tool to quickly analyze lab specimen for infectious diseases including COVID-19. The Cepheid Analyzer provides fast turnaround of lab results to allow the hospital care team to make real time decisions to manage patient care. Thanks to generous donors Barbara and Chick Allen, NVRH received the Cepheid Analyzer in July. “The Allen’s approached us early this year — just prior to the pandemic...

(1) - On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors to accelerate development of its novel vaccine through the end of Phase II trials and preparations for Phase III pivotal trials - Novel vaccine candidate offers viable alternative to antibiotics, thereby strategically aligned with REPAIR Impact Fund's mission to combat antimicrobial resistance (AMR) - - Group B Streptococcus (GBS) is one of the leading causes of stillbirth and infant mortality representing a significant unmet need globally, including in the US and Europe; nearly one i...